Life Sciences Analytics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Life Sciences Analytics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The life sciences analytics market was valued at USD 8,739.99 million in the base year, and it is expected to be worth USD 13,871.66 million during the forecast period while registering a CAGR of 7.91%.

The outbreak of COVID-19 contributed to the rise in demand for analytics, as several clinical trials were conducted for the vaccines for COVID-19. In March 2020, the US Department of Veterans Affairs (VA), Department of Energy (DOE), Department of Health and Human Services (HHS), and National Security Council (NSC) formed the COVID-19 Insights Partnership. The COVID-19 Insights Partnership is leveraging big data analytics tools to research and find possible treatments for the virus. For instance, in November 2021, a predictive analytics model was developed based on an artificial neural network (ANN) model to predict the future number of daily cases and deaths caused by COVID-19 in a generalized way. It showed approximately 86% overall accuracy in predicting the mortality rate and 87% in predicting the number of cases. Thus, life sciences analytics models have proven to be effective in the wake of the COVID-19 pandemic, contributing to market growth. Hence, the COVID-19 pandemic has had a significant positive impact on the market studied. Additionally, due to the significance of analytics, the demand for life science analytics is expected to grow considerably in the future.

The significant factors for the growth of the life sciences analytics market include the rising adoption of analytics solutions in pharmaceuticals and clinical trials, growing pressure to reduce healthcare spending, the need for improved patient outcomes, and the emergence of advanced analytics methods in life science companies.

There is a rise in the use of analytics in clinical trials, as conducting clinical trials has become complex because it involves various activities and generates high volumes of data from different systems. With the changing regulatory protocol requirements for clinical trial conduction and the challenges in data collection, analysis, and preparation of a report quickly for submission to the health authority, the adoption of analytics for clinical trials is on the rise. For instance, in June 2021, IQVIA launched a SaaS-based clinical data analytics platform, Clinical Data Analytics Suite (CDAS), for rapid and intelligent clinical trials.

The emergence of advanced analytics in life science companies is also one of the major factors driving market growth. The 2021 ISG Provider Lens Life Sciences Digital Services Report revealed that life sciences companies in the European region are interested in using analytics to support marketing and sales efforts and optimize supply chain operations. Several other companies are also developing analytics solutions, boosting the adoption and use of analytics solutions. For instance, in September 2021, ZS launched ZAIDYN, a platform for life sciences companies of all sizes to digitally transform and scale customer engagement, field performance, analytics, and clinical capabilities. The emergence of such solutions and products encourages life science companies to develop more advanced analytics solutions, thereby boosting market growth.

In June 2021, JADBio entered into a distribution agreement with QIAGEN to sell and distribute the JADBio offering within the QIAGEN Digital Insights portfolio. JADBio is an AutoML platform with leading-edge AI tools and automation capabilities. It is built to enable life-science professionals to build and deploy accurate and interpretable predictive models quickly and timely, regardless of their data science expertise. Thus, the participation of life sciences companies in developing advanced analytics contributes to market growth.

Thus, factors such as new launches by companies, strategic partnerships, and increasing focus on the implementation of analytics in life sciences are expected to boost the market's growth significantly over the forecast period.

However, a lack of skilled personnel and high implementation costs are expected to restrain the market growth during the forecast period.

Analytics in clinical research helps pharmaceutical companies analyze data for the comparison of ongoing trials at different sites and populations, prepare reports for submission to the regulatory authority, and get approvals.

The roles of the pharmaceutical companies are to invest in the research and development of new compounds, commit to bringing new drugs to the market to enhance patients’ health and quality of life, maintain strict governance when conducting clinical trials, and conduct product development activities for patients and healthcare professionals, following ethical and legal principles.

In October 2021, Ever Fortune.AI and Medexprim announced their strategic partnership dedicated to improving healthcare analytics and medical AI development. This collaboration will expand both companies’ networks of hospitals, further connect healthcare innovations between Asia and Europe, bring value to Taiwanese and European hospitals, and strengthen their research ecosystem, bringing a broader mix of General Data Protection Regulation across Europe. It will also allow meeting pharmaceutical companies’ needs for patient insights for clinical trials, particularly in oncology and cardiology.

Moreover, in the current scenario, where there is high competition from other major companies, analytics benefits the pharmaceutical and biotech industry. For instance, analytics has helped accelerate drug discovery, optimize clinical trials, and effectively target a specific patient population. For example, in March 2022, the leading research-driven biopharmaceutical company Boehringer Ingelheim and precision medicine software company Lifebit Biotech Ltd entered into a partnership in which Lifebit will support Boehringer Ingelheim in building a scalable data, analytics, and infrastructure platform within its IT environment.

In addition, analytics plays a vital role in getting insights into patient behavior to improve drug delivery and the effectiveness of healthcare. Hence all these factors mentioned above are contributing to the segment's growth.

North America holds a significant share of the life science analytics market as the region is well-established in terms of healthcare R&D. In addition, a considerable rise in healthcare spending by the government and the increasing importance of life science analytics in drug development are other factors fueling the market growth in the region.

Analytics is required to track those trials and manage the companies' data, which helps understand the components needed for new drug discovery or drug development. For instance, in March 2022, the SDG Group entered into a partnership with Snowflake, as the company launched the Healthcare and Life Sciences Data Cloud to bring better patient care and business results. It will enable the SDG group to successfully and securely unlock the power of data and analytics to maximize business value.

The life sciences and pharmaceutical industries face R&D and regulatory changes challenges. The introduction of the Affordable Care Act (ACA) in United States is changing the regulatory framework, increasing scrutiny and reimbursing based on health outcomes. To tackle these challenges, most companies in United States are implementing analytics independently or using third-party analytics services for support.

Analytics solutions create an impact that provides simple reporting solutions to descriptive and predictive analytic solutions. The companies based in United States are adopting new analytics solutions in their business, which include the analysis of clinical research data from the SAS database, helpful in early-stage drug development, analyzing adverse event incidence and reporting in clinical trials, and revenue forecasting and prediction of health outcomes. For instance, in September 2021, Honeywell acquired Performix Inc., a manufacturing execution system (MES) software provider for the pharmaceutical and biotech industries. The acquisition was focused on developing an integrated software platform for customers in the life sciences industry, striving to achieve faster compliance, improved reliability, and better production throughput at the highest levels of quality.

Canada is also witnessing significant growth in the market studied owing to the increasing focus of the Canadian government on the development of the life sciences industry. For instance, data published by the Canadian Government in August 2022 stated that the government took decisive action to ensure access to critical vaccines, therapeutics, and other life-saving medicines by developing a comprehensive strategy to re-build a strong and resilient domestic biomanufacturing and life sciences sector. This initiative by the Canadian government is expected to fuel the life sciences analytics industry in the coming years.

With the life sciences and pharmaceutical companies leveraging support from third-party solution providers in clinical development, trial planning, cohort building, market analytics, and patient analytics, the US market for life science analytics is expected to witness high growth over the forecast period.

The market studied is moderately competitive, owing to the presence of various players. Some market players are Accenture, Cognizant, IBM Corporation, MaxisIT Inc., Oracle Corporation, IQVIA, SAS Institute Inc., SCIOInspire Corp., TAKE Solutions Limited, and Wipro Limited. Market players readily adopt critical strategies such as partnerships and acquisitions to strengthen their market portfolio.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support